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Abstract 
  A series of novel isocombretastatin A-4 (isoCA-4) analogs were designed and 
synthesized by replacing 3,4,5-trimethoylphenyl and isovanillin of isoCA-4 with 
quinoline and indole moieties, respectively. The structure activity relationships (SARs) 
of these synthesized quinoline-indole derivatives have been intensively investigated. 
Two compounds 27c and 34b exhibited the most potent activities against five cancer 
cell lines with IC50 values ranging from 2 to 11 nM, which were comparable to those 
of Combretastatin A-4 (CA-4, 1). Further mechanism investigations revealed that 34b 
effectively inhibited the microtubule polymerization by binding to the colchicine site 
of tubulin. Further cellular mechanism studies elucidated that 34b disrupted cell 
microtubule networks, arrested the cell cycle at G2/M phase, induced apoptosis and 
depolarized mitochondria of K562 cells. Moreover, 34b displayed potent anti-vascular 
activity in both wound healing and tube formation assays. Importantly, 27c and 34b 
significantly inhibited tumor growth in H22 xenograft models without apparent 
toxicity, suggesting that 27c and 34b deserve further research as potent antitumor 
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agents for cancer therapy. 
Key words: quinoline; indole; microtubule; tubulin inhibitor; colchicine binding 
site; antitumor  
 
1. Introduction 
CA-4 (1) (Figure 1) was a natural cis-stilbene derivative which was isolated from 
the bark of the African willow tree Combretum caffrum [1]. It has been identified as a 
typical tubulin polymerization inhibitor that target the colchicine binding site [2]. 
CA-4 displayed potent cytotoxicity against a wide range of cancer cell lines including 
multidrug resistant (MDR) cells at nanomolar levels [3]. Moreover, CA-4P, the 
phosphate prodrug of CA-4, induced vascular shutdown within tumors at doses less 
than one-tenth of the maximum tolerated dose, demonstrating the clinical potential of 
CA-4P as vascular disrupting agent [4]. CA-4P had been evaluated in clinical trials, 
however, it had been discontinued due to the lack of a meaningful improvement in 
progression-free survival (PFS) and unfavorable partial response data [5]. The 
Z-isomer of CA-4 is prone to isomerization to produce the E-isomer during storage, 
administration and metabolization, that is significantly less potent at inhibiting tubulin 
polymerization and cancer cell growth [6,7]. The isomerization could be avoided by 
the discoveries of Phenstatin (3) and isoCA-4 (4) [8,9]. IsoCA-4 held the similar 
properties as CA-4 but was more metabolically stable than CA-4 [10]. Other similar 
1,1-diarylethylene derivatives such as compounds 5-9, which have more restricted 
conformations than isoCA-4, were also discovered [11-14]. Another interesting 
isoCA-4 analog 10 was synthesized by replacing two hydrogens of the olefinic linker 
of isoCA-4 with two fluorine atoms, which was about 3-fold more potent than 
isoCA-4 against HCT-116 cells [15]. 
 
Fig. 1. CA-4, isoCA-4 and isoCA-4 analogs. 
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Nitrogenous heterocycles have been utilized in the construction of colchicine 
binding site inhibitors (CBSIs) [16, 17]. Quinazoline containing compounds such as 
11-15 (Fig. 2) were discovered with potent anti-tubulin activities [18-22]. Recently, 
isoCA-4 analog 16 with a quinoline moiety was reported by Alami’s group, and the 
docking studies of 16 showed that the N-1 atom of quinoline formed a hydrogen bond 
with the critical residue Cys 241 [23, 24], which demonstrated that quinoline moiety 
might be a surrogate of the traditional 3,4,5-trimethoylphenyl moiety when binding to 
the colchicine site. Meanwhile, indole moiety has also been found to occur in the 
structures of CBSIs, especially for the replacement of isovanillin ring [25-27]. CA-4 
analog 17 and isoCA-4 analogs 18, 19 containing indole moieties were discovered 
with both potent anti-tubulin and antitumor activities [28-30].  
In recent years, our group has focused on discovering and developing novel 
anti-cancer agents targeting tubulin-microtubule system, such as chalcone analogs 
bearing vinyl sulfone skeleton [31], 4-arylisochromenes [32], and quinazolines that 
occupy three zones of colchicine domain [33]. In this work, we further designed a 
series of novel quinoline-indole derivatives by replacing 3,4,5-trimethoylphenyl and 
isovanillin moieties of isoCA-4 with quinoline and indole rings, respectively (Fig. 2). 
Herein, we report the synthesis and evaluation of their anticancer activities in vitro 
and in vivo. In addition, the underlying cytotoxic mechanisms of the representative 
compound 34b are also elucidated. 
 
Fig. 2. Design strategy of quinoline-indole derivatives as isoCA-4 analogs. 
 
2. Results and discussion 
2.1 Chemistry 
Quinoline-indole derivatives 26a-d with different substituted positions on the 
indole ring were synthesized by the method in Alami’s report [23] as shown in 
Scheme 1. Acetylindoles 21a-c were prepared by three different methods. 
3-Acetyl-6-methoylindole (21a) was synthesized by a Vilsmeier-Haack reaction of 
6-methoylindole (20) in the presence of phosphoryl chloride and dimethylacetamide. 
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Nucleophilic attack on the aldehyde of indole-4-aldehyde (22) by methylmagnesium 
bromide (CH3MgBr) followed by oxidization produced 4-acetylindole (21b). 
5-Acetylindole (24) was prepared by the reaction of indole-5-acid (23) with lithium 
methide (CH3Li), the N-1 of which was then protected to afford N-Boc-5-acetylindole 
(21c). Subsequently, acetylindoles 21a-c were transformed into their corresponding 
N-tosylhydrazones 25a-c which were then coupled with 4-chlorine-2-methylquinoline 
via Pd-catalyzed cross coupling reactions to afford target compounds 26a-c in 
moderate to good yields, and 26c was deprotected to produce 26d. 
 
Scheme 1. The synthetic route for target compounds 26a-da. 
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aReagents and conditions: (a) POCl3, DMA, 0  to rt, 2 h, 89.6%; (b) i) CH3MgBr, THF, 0  to rt, 
1 h; ii) IBX, DMSO; 35.2% over two steps; (c) CH3Li, THF, rt, 1 h, 72.9%; (d) NaH, (Boc)2O, 
THF, rt, 1 h, 79.9%; (e) p-Toluenesulfonhydrazide, EtOH, 90 , 2 h; (f) 
4-Chlorine-2-methylquinoline, PdCl2(CH3CN)2, Xphos, t-BuOLi, 90 , 2 h, 50.2-70.5%; (g) 
K2CO3, CH3OH, reflux, 2 h, 90.9%. 
 
Scheme 2. The synthetic route for target compounds 27a-d, 28a-c, 30a-c and 33a-ca. 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
N
Cl
N
N
OCH3
R
N
N
OCH3
H2N
c d
N
COOH
e
N
COCl
c
N
O N
OCH3
R
d
N
O N
OCH3
NH2
29 30a, R = H;
30b, R = NO2
30c
31 32 33a, R = H;
33b, R = NO2
33c
27a: C-3, R = OCH3, R' = CH3;
27b: C-4, R = H, R' = CH3;
27c: C-5, R = H, R' = CH3;
27d: C-5, R = H, R' = C2H5
28b: C-4;
28c: C-5
26a: C-3, R = OCH3;
26b: C-4, R = H;
26d: C-5, R = H
a
b
28a
b
N
NH
OCH3
N
4
6
7
8
9 NH 1
23
R
10
N
4
6
7
8
9 N
1
23
R
10
R'
N
N
5 5
 
Reagents and conditions: (a) NaH, CH3I or C2H5I, THF, 0  to rt, 30 min, 72.0-85.2%; (b) Pd/C, 
H2, CH3OH, overnight, rt, 60.0-72.3%; (c) NaH, 5-methoylindole or 4-nitro-5-methoylindole, 
DMF, 50 , 25.5-39.4%; (d) Fe, AcOH, EtOH, reflux; 68.0-72.2%; (e) Oxalyl chloride, DMF 
(cat.), DCM, 0  to rt, 30 min.  
 
  Methyl or ethyl groups were introduced to N-1 position of 26a, 26b and 26d to 
afford target compounds 27a-d (Scheme 2). 26a, 27b, and 27c were then reduced in 
the presence of Pd/C under H2 atmosphere to give target compounds 28a-c as racemic 
mixtures. Compounds 30a-c and 33a-c, of which quinoline moieties were substituted 
at N-1 position of indole, were also synthesized using 4-chlorine-2-methylquinoline 
(29) and 2-methylquinoline-4-acid (31) as the starting materials, respectively. 
Compounds 34a-c with different substitutions at N-1 position of indole were also 
synthesized as depicted in Scheme 3.  
  Target compounds 35a-i that have different substitutions at C-2 position of 
quinoline were synthesized as outlined in Scheme 4. Aldehyde 35a was produced by 
the oxidation of 27c in the presence of selenium dioxide (SeO2), followed by 
reduction with sodium borohydride (NaBH4) to give compound 35b. Target 
compounds 35c-i were prepared by the cross-coupling reactions with various C-2 
substituted quinolines 36c-i and N-tosylhydrazone 37. 
 
Scheme 3. The synthetic route for target compounds 34a-ca. 
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aReagents and conditions: (a) NaH, ClCH2F, DMF, sealed tube, 80 , 2 h, 18.0%; (b) 10% NaOH 
aqueous, HCHO aqueous, EtOH, rt, 2 h, 64.9%; (c) Ac2O, Et3N, DCM, reflux, overnight, 78.9%. 
 
Scheme 4. The synthetic route for target compounds 35a-ia. 
 
aReagents and conditions: (a) SeO2, EtOH, 80 , 2 h, 38.5%; (b) NaBH4, THF, rt, 30 min, 75.0%; 
(c) PdCl2(CH3CN)2, Xphos, t-BuOLi, 90 , 2 h, 40.7-80.0%. 
 
2.2 In vitro antiproliferative studies 
To identify the best substituted position on the indole ring, fourteen compounds 
26a-d, 27a-c, 28a-c, 30a, 30c, 33a and 33c were evaluated first for their 
antiproliferative activities against K562 cells. As shown in Table 1, compounds 26a, 
26b, 27b, 28a and 28b, of which olefin was substituted at C-3 and C-5 position on the 
indole rings, displayed lower activities (IC50 > 1 µM) than the C-4 substituted 
counterparts 26d, 27c and 28c. Besides, the methyl substituted at N-1 position of 
indole (27c) significantly increased the activity for about 60 folds when compared to 
the non-substituted counterpart 26d. The reduction of the olefin declined the activity 
as compared by 27c and 28c. Compounds 30a, 30c, 33a and 33c, of which quinoline 
moieties were linked to N-1 position of indole rings, were also designed and evaluated 
for their activities, and the results showed that compounds 30c and 33c with amino 
groups substituted at C-4 position of indole rings exhibited decent activities. 
Furthermore, the effects of substitutions at N-1 position of indole ring on activity were 
investigated, compounds containing methyl (27c, IC50 = 2 nM) and hydroxymethyl 
(34b, IC50 = 2 nM) groups were more potent than other groups including ethyl (27d, 
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IC50 = 31 nM), fluoride methyl (34a, IC50 = 153 nM), or acetyl (34c, IC50 = 179 nM). 
Moreover, the effects of substitutions at C-2 position of quinoline moiety on activity 
were studied, compounds 35a (CHO), 35b (CH2OH), 35c (dimethylamino), 35d 
(OCH3), 35e (NHCH3), 35f (H), 35g (CN), 35h (CONH2) and 35i (CF3) all exhibited 
less potent activities than 27c (CH3). 
  Five cancer cell lines including human hepatocellular carcinoma (HepG2), 
epidermoid carcinoma of the nasopharynx (KB), human colon cancer cells (HCT-8) 
human breast cancer cells (MDA-MB-231), mouse liver cancer cells (H22), and 
human normal hepatocytes LO2 cells were chosen to further evaluate the 
antiproliferative activities of representative compounds. The cytotoxic data in Table 2 
showed that all these selected compounds displayed potent activities against these five 
cancer cell lines in nanomolar ranges, and they also exhibited good selectivities 
against LO2 cells. The K562 cell was the most sensitive cell line among six cancer 
cell lines tested. Compounds 27c and 34b that showed the most potent activities 
against K562 cells also displayed very potent activities against these five cancer cell 
lines with IC50 values ranging from 5 to 11 nM, which were comparable to those of 
CA-4. The overall SARs of synthesized compounds were summarized in Fig. 3. 
 
N R2
N R1
C-5 > N-1 > C-3 > C-4
CH2OH > CH3 > C2H5 > H > FCH2 > Ac
CH3 > NHCH3 > CN > OCH3 > H > CHO > CH2OH > N(CH3)2 > CONH2 > CF3
Substituted at C-5 position of indole is the best
Reduction of the double bond
decreased the activity
CH2OH and CH3 are mostly favored
CH3 is mostly favored
Groups that have large steric hindrance are unfavorable
Fig. 3. Summarized SARs of target compounds. 
 
To investigate whether our compounds are efficacious against drug resistant cancer 
cells, 27c and 34b were tested for their antiproliferative efficacy in the drug-resistant 
and parental sensitive cells using the MTT assay. As shown in Table 3, except for the 
adriamycin-resistant cell line Bel-7402/ADR, the drug-resistant indexes of 27c and 
34b were comparable to those of CA-4, while positive drugs paclitaxel and vincristine 
exhibited 92.5-241.0 folds resistances to the corresponding drug-resistant cells. These 
results indicated that 27c and 34b also exhibited moderate antiproliferative efficacy 
against drug resistant cancer cells. 
Table 1. The antiproliferative activities of all target compounds against K562 cellsa. 
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Compd. IC50 K562 (µM)b Compd. IC50 K562 (µM)b 
26a 
 
> 1 33c 
 
0.289 ± 0.032 
26b 
 
> 1 34a 
 
0.153 ± 0.015 
26c 
 
> 1 34b 
 
0.002 ± 0.001 
26d 
 
0.121 ± 0.012 34c 
 
0.179 ± 0.010 
27a 
 
0.106 ± 0.009 35a 
 
0.094 ± 0.006 
27b 
 
> 1 35b 
 
0.123 ± 0.011 
27c 
 
0.002 ± 0.001 35c 
 
0.171 ± 0.018 
27d 
 
0.031 ± 0.005 35d 
 
0.046 ± 0.009 
28a 
 
> 1 35e 
 
0.005 ± 0.001 
28b 
 
> 1 35f 
 
0.090 ± 0.007 
28c 
 
0.037 ± 0.009 35g 
 
0.008 ± 0.001 
30a 
 
> 1 35h 
 
0.282 ± 0.025 
30c 
 
0.079 ± 0.005 35i 
 
0.446 ± 0.035 
3a 
 
> 1 CA-4 
 
0.007 ± 0.001 
a
 Cells were treated with different concentrations of the compounds for 72 h. Cell viability was measured by the 
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MTT assay as described in the Experimental Section. 
b
 IC50 values are indicated as the mean ± SD (standard error) of at least three independent experiments. 
 
Table 2. Antiproliferative activities of representative compounds against five cancer cell lines and 
normal human liver cellsa. 
 
Compd. 
IC50 values (µM)b 
HepG2 KB HCT-8 MDA-MB-231 H22 LO2 
26d 0.377 ± 0.022 0.372 ± 0.035 0.403 ± 0.040 0.204 ± 0.021 0.184 ± 0.020 0.881 ± 0.105 
27c 0.011 ± 0.002 0.008 ± 0.001 0.009 ± 0.001 0.009 ± 0.002 0.008 ± 0.001 0.088 ± 0.021 
28c 0.101 ± 0.018 0.109 ± 0.013 0.096 ± 0.009 0.103 ± 0.009 0.120 ± 0.012 0.214 ± 0.015 
34b 0.006± 0.001 0.005 ± 0.001 0.007 ± 0.001 0.006 ± 0.001 0.006 ± 0.001 0.048 ± 0.010 
35d 0.053± 0.011 0.084 ± 0.014 0.103 ± 0.015 0.112 ± 0.015 0.105 ± 0.010 0.197 ± 0.032 
35e 0.020± 0.004 0.008 ± 0.002 0.010 ± 0.001 0.027 ± 0.005 0.025 ± 0.003 0.085 ± 0.020 
35g 0.011± 0.002 0.022 ± 0.003 0.028 ± 0.004 0.034 ± 0.005 0.022 ± 0.004 0.055 ± 0.011 
CA-4 0.009± 0.002 0.011 ± 0.002 0.011 ± 0.002 0.011 ± 0.003 0.010 ± 0.002 0.046 ± 0.010 
a
 Cells were treated with different concentrations of the compounds for 72 h. Cell viability was measured by the 
MTT assay as described in the Experimental Section. 
b
 IC50 values are indicated as the mean ± SD (standard error) of at least three independent experiments. 
 
Table 3. The IC50 values of representative compounds in different drug-resistant cancer cells. 
 
Compd. 
                                       IC50 values (µM)a   
HCT-8 HCT-8/Taxol DRIb A549 A549/Taxol DRI K562 K562/VCR DRI Bel-7402 Bel-7402/ADR DRI 
27c 
0.009 ± 
0.001 
0.098 ± 
 0.018 
10.9 
0.025± 
0.002 
0.342 ±  
0.032 
13.7 
0.002 ± 
0.001 
0.030 ± 
0.003 
15 
0.028 ±  
0.003 
0.185 ±  
0.022 
6.6 
34b 
0.007 ± 
0.002 
0.088 ± 
 0.022 
12.6 
0.009 ± 
0.002 
0.119 ±  
0.022 
13.2 
0.002 ± 
0.001 
0.031 ± 
0.005 
15.5 
0.010 ±  
0.002 
0.061 ±  
0.009 
6.1 
CA-4 
0.011 ± 
0.002 
0.087 ±  
0.005 
7.9 
0.009 ± 
0.002 
0.175 ±  
0.022 
19.4 
0.007 ± 
0.001 
0.057±  
0.012 
8.1 
0.011 ±  
0.002 
0.058 ±  
0.002 
5.3 
ADR NDc ND - ND ND - ND ND - 
0.274 ±  
0.086 
1.732 ± 
 0.202 
6.3 
Taxol 
0.028 ± 
0.004 
2.590 ± 
 0.122 
92.5 
0.018 ± 
0.004 
1.830 ±  
0.104 
101.6 ND ND - ND ND - 
VCR ND ND - ND ND - 
0.021± 
0.004 
5.060 ± 
0.562 
241.0 ND ND - 
a Data are presented as the mean ± SD from the dose-response cures of at least three independent experiments. 
b DRI: drug-resistant index = (IC50 of drug resistant cancer cell) / (IC50 of parental cancer cell). 
c ND: not detected. 
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2.3 In vitro tubulin polymerization inhibitory assay 
To elucidate whether these quinoline-indole derivatives target the 
tubulin-microtubule system, two most potent compounds 27c and 34b were evaluated 
for their effects on microtubule dynamics of K562 cells. The typical 
microtubule-destabilizing agent (MDA) colchicine and microtubule-stabilizing agent 
taxol were employed as the controls. As shown in Fig. 4, taxol exhibited a significant 
promotion of tubulin polymerization, while colchicine produced a significant 
inhibition of tubulin polymerization. Compounds 27c and 34b displayed similar 
actions to that of colchicine, indicating that 27c and 34b were MDAs. The calculated 
IC50 values of 27c and 34b in inhibiting tubulin polymerization were 2.54 and 2.09 
µM, respectively, which were comparable to that of CA-4 (IC50 = 2.12 µM) (Table 4). 
In addition, 27c and 34b competed with [3H]-colchicine in binding to tubulin. The 
binding potency of 27c and 34b to the colchicine binding site was 89.4% and 90.5% 
at 5 µM, respectively (Table 4), indicating that 27c and 34b bind to the colchicine 
binding site. Therefore, taking considerations of the good activities of compound 34b 
showing both in the in vitro antiproliferative assay and tubulin polymerization 
inhibition assay, it was selected for further mechanism studies. 
 
O
.
D
34
0 
n
m
0 5 10 15 20 25 30 35 40 45 50 55 60
0.0
0.2
0.4
0.6
0.8 ctrl
Taxol 10 µM
Colchicine 10 µM
27c 5 µM
27c 10 µM
Time (min)
34b 5 µM
34b 10 µM
 
Fig. 4. Effects of 27c and 34b on tubulin polymerization in vitro. Purified tubulin protein at 2 
mg/mL in a reaction buffer was incubated at 37 °C in the presence of 1% DMSO, test compounds 
(27c at 5 or 10 µM), (34b at 5 or 10 µM), Colchicine (10 µM) or Taxol (10 µM). Polymerizations 
were followed by an increase in fluorescence emission at 350 nm over a 60 min period at 37 °C. 
The experiments were performed three times. 
 
Table 4. Inhibition of tubulin polymerizationa and colchicine binding to tubulinb 
Compd. 
Inhibition of tubulin polymerizaion 
Inhibition of colchicine binding 
(%) inhibition ± SD 
IC50 (µM) 1 µM 5 µM 
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27c 2.54 ± 0.13 78.4 ± 1.9 89.4 ± 2.2 
34b 2.09 ± 0.20 79.4 ± 2.2 90.5 ± 2.5 
CA-4 2.12 ± 0.10 80.2 ± 2.1 91.5 ± 4.0 
a The tubulin assembly assay measured the extent of assembly of 2 mg/mL tubulin after 60 min at 
37 °C. Data are presented as mean from three independent experiments.  
b
 Tubulin, 1 µM; [3H]-colchicine, 5 µM; and inhibitors, 1 or 5 µM. 
 
2.4. Anti-microtubule effects in K562 cells 
  To study whether 34b could disrupt the microtubule dynamics in living cells, 
immunofluorescent assay in K562 cells were performed. As shown in Fig. 5, K562 
cells in the control group exhibited normal arrangement and organization. However, 
after treatments with 34b (1 nM, 2 nM, and 4 nM) for 24 h, the microtubule networks 
in cytosol were disrupted; these results indicated that 34b can induce a 
dose-dependent collapse of the microtubule networks. 
 
 
Fig. 5. Effects of 34b on the cellular microtubule networks visualized by immunofluorescence. 
K562 cells were treated with vehicle control 0.1% DMSO, 34b (1 nM), 34b (2 nM), and 34b (4 
nM). Then, the cells were fixed and stained with anti-α-tubulin−FITC antibody (green), Alexa 
Fluor 488 dye and counterstained with DAPI (blue). The detection of the fixed and stained cells 
was performed with an LSM 570 laser confocal microscope (Carl Zeiss, Germany). 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
2.5 Cell cycle analysis 
As most tubulin destabilizing agents could disrupt the cell cycle distribution, a flow 
cytometry analysis was performed to examine the effect of 34b on K562 cell cycle 
progression using a propidium iodide (PI) staining assay. As illustrated in Fig. 6a and 
6b, incubation with 34b blocked the cell cycle at the G2/M phase. Compared to the 
control cells incubated with DMSO, the incubation of K562 cells with increased 
concentrations of 34b (1, 2, and 4 nM) increased the percentage of cells at the G2/M 
phase from 10.51% to 23.21%. 
 
 
Fig. 6. (A) Compound 34b induced G2/M arrest in K562 cells. K562 cells were incubated with 
varying concentrations of 34b (0, 1, 2, and 4 nM) for 48 h. Cells were harvested and stained with 
PI and then analyzed by flow cytometry. The percentages of cells in different phases of cell cycle 
were analyzed by ModFit 4.1. (B) Histograms display the percentage of cell cycle distribution 
after treatment with 34b. 
 
2.6 Cell apoptosis analysis 
To assess whether compound 34b would induce cell apoptosis, an Annexin 
V-FITC/PI assay was carried out. As shown in Fig. 7A and 7B, compound 34b 
induced K562 cell apoptosis in a dose-dependent manner. The percentage of apoptotic 
cells after 48 h treatment was only 5.96% in the control group. When the cells were 
incubated with 34b at 1, 2, and 4 nM for 48 h, the total numbers of early 
(Annexin-V+/PI−) and late (Annexin-V+/PI+) apoptotic cells were 25.7%, 54.9% and 
72.8%, respectively. These results demonstrated that compound 34b effectively 
induced cell apoptosis of K562 cells in a dose-dependent manner. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
Fig. 7. (A) Compound 34b induced apoptosis in K562 cells. K562 cells were incubated with 
varying concentrations of 34b (0, 1, 2, and 4 nM). After 48 h of incubation, cells were collected 
and stained with Annexin V/PI, followed by flow cytometric analysis. The percentages of cells in 
each stage of cell apoptosis were quantified by flow cytometry: (upper left quadrant) necrosis cells; 
(upper right quadrant) late-apoptotic cells; (bottom left quadrant) live cells; and (bottom right 
quadrant) early apoptotic cells. (B) Histograms display the percentage of cell distribution after 
treatment with 34b. 
 
2.7 Mitochondrial membrane potential analysis. 
In order to determine whether 34b-induced apoptosis was involved in a disruption 
of mitochondrial membrane integrity, the fluorescent probe JC-1 was employed to 
measure the mitochondrial membrane potential (MMP). When treated with 34b at 
concentrations of 0, 1, 2 and 4 nM for 48 h, the number of K562 cells with collapsed 
MMP increased from 6.17% to 28.99%, 45.10% and 73.55%, respectively. (Fig. 8), 
suggesting that 34b caused mitochondrial depolarization of K562 cells in the process 
of apoptosis. 
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Fig. 8. Effects of 34b on the mitochondrial membrane potential of K562 cells. (A) Incubation with 
different concentrations (0, 1, 2, and 4 nM) of 34b in K562 cells for 48 h prior to staining with 
JC-1 dye, the number of cells with collapsed mitochondrial membrane potentials was determined 
by flow cytometry analysis. (B) Histograms display the percentage of green fluorescence. 
 
2.8 In vitro evaluation of anti-vascular activity 
To evaluate the anti-vascular activity of compound 34b, the human umbilical vein 
endothelial cells (HUVECs) culture assays were firstly performed to assess the ability 
of 34b to inhibit HUVECs migration which is the key step to generate new blood 
vessels. As shown in Fig. 9A, the untreated cells migrated to fill the area that was 
initially scraped after 24 h. In contrast, 34b significantly inhibited the HUVEC 
migration in a dose-dependent manner (Fig. 9C).  
The HUVEC tube formation is the key step in angiogenesis, including proliferation, 
adhesion, and the formation of tube-like vascular structures. Then, we evaluated the 
anti-vascular activity of 34b in a tube formation assay. After being seeded on Matrigel, 
HUVECs form the capillary-like tubules with multicentric junctions (Fig. 9B, the 
control group), while 34b inhibited HUVEC cord formation in a 
concentration-dependent manner at concentrations (1, 2 and 4 nM) that had minimal 
effects on HUVEC proliferation after treated with 34b for 6 h. These results showed 
that compound 34b effectively inhibited the tube formation of HUVECs. 
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Fig. 9. Effects on the HUVECs migration and tube formation. (A) Scratches were created with 
sterile 200 µL pipette and images were captured using phase contrast microscopy at 0 h and 24 h 
after treatments with 0, 1, 2 and 4 nM of 34b. (B) Images depicting the formation of HUVEC 
capillary-like tubular network by treatments with 0, 1, 2 and 4 nM of 34b for 6 h. (C) Histograms 
display the length of the scratches at 0 h and 24 h after treatments with 0, 1, 2 and 4 nM of 34b, 
*** P < 0.001, vs control group. 
 
2.9 In vivo antitumor activity of 27c and 34b 
To evaluate the in vivo antitumor activities of 27c and 34b, liver cancer xenograft 
mouse model was established by subcutaneous inoculation of H22 cells into the right 
flank of mice. The tumor size and body weights of the mice were monitored and 
recorded every 2 days. Paclitaxel (PTX), CA-4 and the disodium phosphate of CA-4 
(CA-4P) were selected as the positive controls. As shown in Fig. 10A and Fig. 10B, 
27c and 34b at the dose of 20 mg/kg per day significantly decreased the tumor 
volume. The reduction in tumor weight reached 72.7% at a dose of 6 mg/kg per 2 
days (i.v.) of PTX at 21 days after initiation of treatment as compared to vehicle, 
while 27c and 34b reduced tumor weights by 63.7% and 57.3% at doses of 20 mg/kg 
per day (i.v.), respectively. Notably, 27c at the dose of 20 mg/kg displayed more 
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potent antitumor activity than CA-4 (inhibition rate: 51.0% at 20 mg/kg) or CA-4P 
(inhibition rate: 62.7% at 20 mg/kg) (Fig. 10D). Moreover, 27c and 34b did not 
significantly affected body weight even at the doses of 20 mg/kg, while treatment 
with PTX at a dose of 6 mg/kg per 2 days had significant effects on body weight (Fig. 
10C). Thus, compounds 27c and 34b are worthy of further investigations for the 
treatment of cancers. 
 
Fig. 10. 27c and 34b inhibited liver cancer xenograft growth in vivo. After administered with 
vehicle, PTX (6 mg/kg per 2 days), 27c (10 mg/kg per day), 27c (20 mg/kg per day), 34b (10 
mg/kg per day), 34b (20 mg/kg per day), CA-4 (20 mg/kg per day), and CA-4P (20 mg/kg per day) 
for three weeks, the mice were sacrificed, and the tumors were weighted. (a) The images of 
tumors from mice at 21 days after initiation of treatment. (b) Tumor volume changes of mice 
during treatment. (c) Body weight changes of mice during treatment. (d) The weight of the excised 
tumors of each group. **P < 0.05, ***P < 0.001, vs control group. 
2.10 Molecular modelling studies 
To illustrate the binding modes of two most active compounds 27c and 34b with 
tubulin, we performed a docking study of 27c and 34b into the colchicine binding 
pocket of tubulin (PDB: 5lyj) by using the DOCK program in the Discovery Studio 
3.0 software. As shown in Fig. 11A and Fig. 11B, 27c or 34b and CA-4 adopted very 
similar positioning at the colchicine binding pocket. The N-1 of quinoline moiety 
formed hydrogen bonds with residue Cys241, which were similar to that of the 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
4-methoyl group of CA-4. The indole rings extended into the hydrophobic pocket 
which was surrounded by residues Thr179, Val315, Asn350 and Val351. The 
hydroxymethyl group of 34b formed two additional hydrogen bonds with Val315 and 
Asn350, which might explain the slight difference in activity between 27c and 34b. 
The binding modes of 27c and 34b resembled to that of compound 16 predicted by 
Alami’s group [23], which further demonstrated that quinoline moiety is a surrogate 
of the traditional 3,4,5-trimethoylphenyl moiety when binding to the colchicine site. 
 
Fig. 11. (A) Proposed binding model for 27c (violet) binding with tubulin (PDB code: 5lyj), and 
overlapping with CA-4 (yellow); (B) Proposed binding model for 34b (magenta) binding with 
tubulin (PDB code: 5lyj), and overlapping with CA-4 (yellow). 
 
3. Conclusion 
In summary, we have designed, synthesized, and evaluated a series of novel 
quinoline-indole derivatives as tubulin polymerization inhibitors for cancer therapy. 
The SARs of these synthesized quinoline-indole derivatives have been intensively 
investigated. Two compounds 27c and 34b exhibited the most potent activities against 
five cancer cell lines with IC50 values ranging from 2 to 11 nM, which were 
comparable to those of CA-4. 27c and 34b also displayed moderate selectivity for 
human normal hepatocytes LO2 cells, which might indicate their low toxicities. 
Besides, 27c and 34b exhibited moderate antiproliferative efficacy against several 
drug resistant cancer cells, which were comparable to those of CA-4. Furthermore, 
27c and 34b effectively inhibited tubulin polymerization as MDAs with IC50 values of 
2.54 and 2.09 µM, respectively. Colchicine competition inhibition assay and 
molecular modelling studies indicated that 27c and 34b bind to the colchicine binding 
site. Further mechanism studies demonstrated that 34b disrupted microtubule 
networks, arrested cell cycle at G2/M phase, induced apoptosis and depolarized 
mitochondria of K562 cells with a dose-dependent manner. Furthermore, the wound 
healing and tube formation assays also identified 34b as a novel vascular disrupting 
agent. Finally, the in vivo antitumor activity of 27c and 34b were validated in H22 
liver cancer xenograft mouse model. 27c effectively suppressed the tumor volume and 
reduced tumor weight by 63.7% at the dose of 20 mg/kg per day (i.v.) without 
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apparent toxicity, which was more potent than CA-4 and CA-4P. Collectively, these 
results highlighted the 27c and 34d as novel anti-tubulin agents with clinical potential 
for the treatment of cancers, which deserve to be further investigated.  
 
4. Experimental 
4.1. Chemistry  
4.1.1. General 
Most chemicals and solvents were purchased from commercial sources. Further 
purification and drying by standard methods were employed when necessary. 1H 
NMR and 13C NMR spectra were recorded on Bruker-300 spectrometers in the 
indicated solvents (TMS as internal standard). Data are reported as follows: chemical 
shift in ppm (d), multiplicity (s =singlet, d =doublet, t =triplet, q =quartet, brs = broad 
singlet, m = multiple), coupling constant (Hz), and integration. High Resolution Mass 
measurement was performed on Agilent QTOF 6520 mass spectrometer with electron 
spray ionization (ESI) as the ion source. Flash column chromatography was carried 
out using commercially available silica gel (200-300 mesh) under pressure. 
 
4.1.2 Synthesis of intermediate 21a. 
  To a solution of 6-methoylindole (300 mg, 2.04 mmol) in 5 mL DMA, POCl3 (1.9 
mL, 20.4 mmol) was added at 0 . After stirring for 2 h at room temperature, the 
mixture was basified with 10% NaOH aqueous. The precipitates were collected by 
filtration, washed with water and dried to afford intermediate 21a (346 mg, 89.6%) as 
yellow solid, the crude product was used without further purification. The spectral 
data of 21a was in accordance with literature report [34]. 
 
4.1.3 Synthesis of intermediate 21b. 
To a solution of indole-4-aldehyde (500 mg, 3.45 mmol) in 20 mL anhydrous THF, 
a solution of CH3MgBr in diethyl ether (3 M, 2.87 mL, 8.6 mmol) was added 
dropwise at 0  under N2 atmosphere. After stirring for 1 h, the reaction was 
quenched by NH4Cl aqueous, and extracted with CH2Cl2 (3 × 50 mL). The combined 
organic layers were then washed with brine, dried over anhydrous Na2SO4, and 
concentrated in vacuo to provide 240 mg 1-(1H-indol-4-yl)ethan-1-ol as colorless oil, 
which was dissolved into 10 mL DMSO, and IBX（500 mg, 1.79 mmol）was added in 
one potion. After stirring for 1 h, the mixture was diluted with 50 mL EtOAc, then 
washed with water (20 mL × 3), saturated brine, dried over anhydrous Na2SO4, and 
concentrated in vacuo to afford crude product, which was purified by column 
chromatography with petroleum/ethyl acetate (2:1) to give intermediate 21b (193 mg, 
35.2% over two steps). The spectral data of 21b was in accordance with literature 
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report [35]. 
 
4.1.4 Synthesis of intermediate 21c. 
  To a solution of indole-5-acid (2.5 g, 15.5 mmol) in 30 mL anhydrous THF, a 
solution of CH3Li (1.6 M, 30 mL, 51.2 mmol) in diethyl ether was added dropwise at 
0  under N2 atmosphere. The mixture was stirred at room temperature for 4 h, the 
reaction was quenched by NH4Cl aqueous, and extracted with CH2Cl2 (3 × 50 mL). 
The combined organic layers were then washed with brine, dried over anhydrous 
Na2SO4, and concentrated in vacuo to provide 1.8 g 5-acetylindole (24) as white solid. 
To a solution of 24 (500 mg, 3.14 mmol) in 20 mL anhydrous THF, NaH (60%, 188 
mg, 4.71 mmol) was added and the mixture was stirred for 15 min. Then, (Boc)2O 
(822 mg, 4.71 mmol) was added dropwise. After stirring for 1 h, the mixture was 
diluted with 50 mL EtOAc, then washed with water (20 mL × 3), saturated brine, 
dried over anhydrous Na2SO4, and concentrated in vacuo to afford the crude product, 
which was purified by column chromatography with petroleum/ethyl acetate (5:1) to 
give intermediate 21a (650 mg, 79.9%). The spectral data of 21c was in accordance 
with literature report [36]. 
 
4.1.5 The general procedure for the preparations of compounds 26a-d. 
  To the solutions of various acetylindoles (0.82 mmol) in 10 mL EtOH, 
p-toluenesulfonhydrazide (183 mg, 0.98 mmol) was added. After stirring for 2 h at 
refluxing temperature, the mixtures were cooled to room temperature, and the 
precipitates were collected by filtration, washed with cold EtOH and dried to afford 
corresponding N-tosylhydrazones 25a-c as yellow solids in moderate to excellent 
yields. Then, to the solutions of 25a-c (0.98 mmol) in 2 mL dioxane in sealed tube, 
4-chlorine-2-methylquinoline (40 mg, 0.23 mmol), Xphos (19 mg, 0.04 mmol), 
Pd(CH3CN)2Cl2 (6 mg, 0.02 mmol), t-BuOLi (40 mg, 0.51 mmol) were added. After 
stirring for 2 h at 90 , the mixtures were filtered and the filtrates were concentrated 
to afford the crude products, which were purified by column chromatography with 
petroleum/ethyl acetate (5:1) to give compounds 26a-c in good yields. 
4.1.5.1 4-(1-(6-methoxy-1H-indol-3-yl)vinyl)-2-methylquinoline (26a) 
  Grey solid, yield 50.2%; 1H NMR (300 MHz, CDCl3) δ 8.41 (s, 1H), 8.02 (d, J = 
8.5 Hz, 1H), 7.89 (d, J = 8.4 Hz, 1H), 7.76 (d, J = 8.6 Hz, 1H), 7.65 - 7.55 (m, 1H), 
7.30 (s, 1H), 7.13 - 7.03 (m, 1H), 6.99 - 6.87 (m, 1H), 6.86 - 6.84 (m, 1H), 6.53 (d, J 
= 2.5 Hz, 1H), 6.05 (d, J = 1.4 Hz, 1H), 5.30 (d, J = 1.5 Hz, 1H), 3.84 (s, 3H), 2.75 (s, 
3H); 13C NMR (75 MHz, CDCl3) δ 158.26, 156.13, 152.03, 149.51, 147.50, 139.73, 
137.29, 128.80, 127.94, 125.78, 124.99, 123.72, 121.50, 120.65, 118.94, 116.80, 
112.69, 109.90, 94.45, 55.13, 24.73; HR-MS (ESI) m/z: calcd for C21H19N2O [M+H]+ 
315.1492, found 315.1498. 
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4.1.5.2 4-(1-(1H-indol-4-yl)vinyl)-2-methylquinoline (26b) 
Grey solid, yield 62.5%; 1H NMR (300 MHz, CDCl3) δ 8.54 (s, 1H), 8.04 (d, J = 
8.4 Hz, 1H), 7.86 (dd, J = 8.3, 1.4 Hz, 1H), 7.59 (ddd, J = 8.3, 6.8, 1.4 Hz, 1H), 7.34 
(d, J = 8.0 Hz, 1H), 7.30 (s, 1H), 7.25 (s, 1H), 7.17 (t, J = 2.8 Hz, 1H), 7.08 (s, 1H), 
6.92 – 6.86 (m, 1H), 6.45 (s, 1H), 6.12 (d, J = 1.6 Hz, 1H), 5.66 (d, J = 1.6 Hz, 1H), 
2.75 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 158.19, 149.38, 145.70, 129.39, 128.73, 
128.12, 127.32, 125.47, 125.10, 124.26, 122.17, 121.87, 121.17, 119.37, 119.07, 
110.79, 101.56, 100.63, 100.11, 55.10; HR-MS (ESI) m/z: calcd for C20H17N2 
[M+H]+ 285.1386, found 285.1388. 
4.1.5.3 tert-butyl 5-(1-(2-methylquinolin-4-yl)vinyl)-1H-indole-1-carboxylate (26c) 
Grey solid, yield 70.5%; 1H NMR (300 MHz, CDCl3) δ 8.01 (s, 1H), 7.98 (d, J = 
2.7 Hz, 1H), 7.66 (d, J = 8.4 Hz, 1H), 7.61 - 7.54 (m, 1H), 7.51 (d, J = 3.8 Hz, 1H), 
7.35 - 7.31 (m, 1H), 7.30 - 7.26 (m, 1H), 7.26 - 7.22 (m, 1H), 7.21 (d, J = 4.5 Hz, 1H), 
6.40 (d, J = 3.7 Hz, 1H), 5.95 (s, 1H), 5.33 (s, 1H), 2.72 (s, 3H), 1.59 (s, 9H); 13C 
NMR (75 MHz, CDCl3) δ 158.29, 149.09, 148.45, 147.74, 146.04, 134.23, 130.24, 
128.73, 128.36, 126.09, 125.61, 125.07, 124.95, 122.40, 122.05, 118.88, 115.68, 
114.66, 106.97, 83.38, 27.67, 24.90; HR-MS (ESI) m/z: calcd for C25H25N2O2 
[M+H]+ 385.1911, found 385.1916. 
4.1.5.4 4-(1-(1H-indol-5-yl)vinyl)-2-methylquinoline (26d) 
To a solution of 26c (75 mg, 0.20 mmol) in 10 mL CH3OH, K2CO3 (33 mg, 0.24 
mmol) was added. After stirring for 2 h at refluxing temperature, the mixture was 
extracted with CH2Cl2 (3 × 25 mL). The combined organic layers were then washed 
with brine, dried over anhydrous Na2SO4, and concentrated in vacuo to provide the 
crude product, which was purified by column chromatography with petroleum/ethyl 
acetate (5:1) to give 50 mg 26d as grey solid, yield 90.9%; 1H NMR (300 MHz, 
CDCl3) δ 8.31 (s, 1H), 8.04 (d, J = 8.4 Hz, 1H), 7.79 (dd, J = 8.3, 1.4 Hz, 1H), 7.62 
(ddd, J = 8.4, 6.8, 1.5 Hz, 1H), 7.51 - 7.44 (m, 1H), 7.34 - 7.31 (m, 1H), 7.31 - 7.29 
(m, 1H), 7.29 (s, 1H), 7.23 (dd, J = 8.5, 1.7 Hz, 1H), 7.19 (t, J = 2.8 Hz, 1H), 6.47 – 
6.45 (m, 1H), 5.98 (d, J = 1.2 Hz, 1H), 5.33 (d, J = 1.2 Hz, 1H), 2.78 (s, 3H); 13C 
NMR (75 MHz, CDCl3) δ 158.30, 149.24, 147.65, 146.57, 135.22, 131.48, 128.77, 
128.08, 127.47, 125.87, 125.24, 125.07, 124.60, 122.10, 120.31, 118.86, 114.47, 
110.66, 102.43, 24.80; HR-MS (ESI) m/z: calcd for C20H17N2 [M+H]+ 285.1386, 
found 285.1391. 
4.1.6 The general procedures for the preparations of compounds 27a-d. 
To the solutions of 26a, 26b or 26d (0.16 mmol) in 10 mL anhydrous THF, NaH 
(60%, 10 mg, 0.24 mmol) was added and the mixtures were stirred for 15 min. CH3I 
or C2H5I (0.20 mmol) was added, after stirring for 30 min at ambient temperature, the 
mixtures were extracted with CH2Cl2 (3 × 25 mL). The combined organic layers were 
then washed with brine (25 mL), dried over anhydrous Na2SO4, and concentrated in 
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vacuo. The residues were purified by column chromatography with petroleum/ethyl 
acetate (5:1) an eluent to afford products 27a-d as grey solids in good to excellent 
yields. 
4.1.6.1 4-(1-(6-methoxy-1-methyl-1H-indol-3-yl)vinyl)-2-methylquinoline (27a) 
Grey solid, yield 85.2%; 1H NMR (300 MHz, CDCl3) δ 8.05 (d, J = 8.5 Hz, 1H), 
7.91 (d, J = 7.9 Hz, 1H), 7.78 (d, J = 8.7 Hz, 1H), 7.68 - 7.59 (m, 1H), 7.34 (d, J = 8.3 
Hz, 1H), 7.30 (s, 1H), 6.88 (dd, J = 8.7, 2.3 Hz, 1H), 6.76 (d, J = 2.3 Hz, 1H), 6.40 (s, 
1H), 6.02 (d, J = 1.3 Hz, 1H), 5.24 (d, J = 1.3 Hz, 1H), 3.90 (s, 3H), 3.58 (s, 3H), 2.78 
(s, 3H); 13C NMR (75 MHz, CDCl3) δ 158.23, 156.07, 149.53, 147.54, 141.70, 139.60, 
138.05, 128.79, 128.30, 128.06, 125.78, 125.00, 121.45, 120.88, 119.40, 115.38, 
112.04, 109.47, 92.68, 55.21, 32.31, 24.82; HR-MS (ESI) m/z: calcd for 
C22H21N2O[M+H]+ 329.1648, found 329.1655. 
4.1.6.2 2-methyl-4-(1-(1-methyl-1H-indol-4-yl)vinyl) quinoline (27b) 
Yield 73.5%, grey solid; 1H NMR (300 MHz, CDCl3) δ 8.02 (d, J = 8.5 Hz, 1H), 
7.84 (d, J = 8.8 Hz, 1H), 7.63 - 7.57 (m, 1H), 7.30 (s, 1H), 7.27 (s, 1H), 7.26 (s, 1H), 
7.12 (t, J = 7.8 Hz, 1H), 7.02 (d, J = 3.1 Hz, 1H), 6.88 (d, J = 7.6 Hz, 1H), 6.38 (d, J = 
3.2 Hz, 1H), 6.11 (d, J = 1.7 Hz, 1H), 5.65 (d, J = 1.7 Hz, 1H), 3.80 (s, 3H), 2.75 (s, 
3H); 13C NMR (75 MHz, CDCl3) δ 158.17, 149.20, 147.81, 145.71, 136.69, 132.90, 
128.69, 128.65, 128.53, 128.33, 125.62, 125.41, 125.05, 124.95, 121.82, 120.95, 
119.13, 108.76, 100.22, 32.52, 24.89; HR-MS (ESI) m/z: calcd for C22H19N2[M+H]+ 
299.1543, found 299.1544. 
4.1.6.3 2-methyl-4-(1-(1-methyl-1H-indol-5-yl)vinyl) quinoline (27c) 
Yield 83.4%, grey solid; 1H NMR (300 MHz, CDCl3) δ 8.05 (d, J = 8.4 Hz, 1H), 
7.84 - 7.75 (m, 1H), 7.65 - 7.57 (m, 1H), 7.46 (s, 1H), 7.29 (s, 2H), 7.27 - 7.25 (m, 
1H), 7.25 (s, 1H), 7.02 (d, J = 3.1 Hz, 1H), 6.38 (d, J = 3.1 Hz, 1H), 5.98 (s, 1H), 5.32 
(s, 1H), 3.77 (s, 3H), 2.78 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 158.25, 149.06, 
147.72, 146.63, 136.00, 131.11, 129.06, 128.65, 128.26, 127.94, 125.79, 125.18, 
124.97, 122.03, 119.94, 119.11, 114.35, 108.73, 101.02, 32.42, 24.91; HR-MS (ESI) 
m/z: calcd for C21H19N2[M+H]+ 299.1543, found 299.1543. 
4.1.6.4 2-methyl-4-(1-(1-ethyl-1H-indol-5-yl)vinyl) quinoline (27d) 
Yield 72.0%, white solid; 1H NMR (300 MHz, CDCl3) δ 7.94 (dd, J = 8.5, 1.2 Hz, 
1H), 7.69 (d, J = 7.7 Hz, 1H), 7.47 (ddd, J = 8.4, 6.8, 1.5 Hz, 1H), 7.34 (s, 1H), 7.16 
(s, 1H), 7.14 (s, 1H), 7.11 (s, 1H), 7.11 - 7.10 (m, 1H), 6.92 (d, J = 3.1 Hz, 1H), 6.25 
(d, J = 3.2 Hz, 1H), 5.85 (d, J = 1.3 Hz, 1H), 5.18 (d, J = 1.2 Hz, 1H), 3.94 (t, J = 7.3 
Hz, 2H), 2.65 (s, 3H), 1.27 (t, J = 7.3 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 158.25, 
149.11, 147.71, 146.59, 135.04, 131.04, 128.67, 128.25, 128.11, 127.28, 125.83, 
125.22, 125.00, 122.03, 119.79, 119.21, 114.28, 108.80, 101.15, 40.58, 24.91, 14.99; 
HR-MS (ESI) m/z: calcd for C22H21N2[M+H]+ 313.1699, found 313.1702. 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
4.1.7 The general procedures for the preparations of compounds 28a-c. 
To solutions of 26a, 27b or 27c (0.16 mmol) in 10 mL anhydrous CH3OH, Pd-C (5 
mg) was added and the mixtures were stirred overnight under H2 atmosphere. Then, 
the mixtures were filtered and the filtrates were concentrated. The residues were 
purified by column chromatography with petroleum/ethyl acetate (5:1) to give 
compounds 28a-c in good yields. 
4.1.7.1 4-(1-(6-methoxy-1H-indol-3-yl)ethyl)-2-methylquinoline (28a) 
Yield 72.3%, white solid; 1H NMR (300 MHz, CDCl3) δ 8.23 (s, 1H), 8.10 (d, J = 
8.6 Hz, 1H), 8.00 (d, J = 8.4 Hz, 1H), 7.59 (t, J = 7.7 Hz, 1H), 7.41 (t, J = 7.8 Hz, 1H), 
7.08 (d, J = 8.8 Hz, 1H), 7.04 (s, 1H), 6.80 (s, 1H), 6.77 (s, 1H), 6.60 (d, J = 8.9 Hz, 
1H), 5.04 (d, J = 7.2 Hz, 1H), 3.73 (s, 3H), 2.56 (s, 3H), 1.72 (d, J = 7.0 Hz, 3H); 13C 
NMR (75 MHz, CDCl3) δ 158.44, 156.05, 151.86, 147.67, 147.52, 136.92, 128.84, 
128.42, 125.05, 124.84, 122.74, 120.50, 120.23, 119.41, 119.31, 108.83, 94.19, 55.11, 
31.27, 24.96, 20.84; HR-MS (ESI) m/z: calcd for C21H21N2O[M+H]+ 317.1648, found 
317.1655. 
4.1.7.2 2-methyl-4-(1-(1-methyl-1H-indol-4-yl) ethyl)quinolone (28b) 
Yield 60%, white solid; 1H NMR (300 MHz, CDCl3) δ 8.06 - 8.03 (m, 1H), 8.02 - 
7.99 (m, 1H), 7.60 (ddd, J = 8.4, 6.9, 1.4 Hz, 1H), 7.37 (ddd, J = 8.3, 6.8, 1.3 Hz, 1H), 
7.22 (d, J = 9.6 Hz, 2H), 7.14 (t, J = 7.7 Hz, 1H), 7.02 (d, J = 3.1 Hz, 1H), 6.85 (d, J = 
7.1 Hz, 1H), 6.42 (dd, J = 3.2, 0.9 Hz, 1H), 5.29 (q, J = 7.2 Hz, 1H), 3.79 (s, 3H), 
2.69 (s, 3H), 1.82 (d, J = 7.1 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 158.26, 151.36, 
147.69, 136.55, 136.23, 128.85, 128.65, 128.29, 128.15, 126.79, 125.07, 122.99, 
121.28, 119.60, 116.72, 107.37, 98.55, 36.90, 32.49, 25.14, 20.50; HR-MS (ESI) m/z: 
calcd for C21H21N2[M+H]+ 301.1699, found 301.1702. 
4.1.7.3 2-methyl-5-(1-(1-methyl-1H-indol-4-yl) ethyl)quinolone (28c) 
Yield 70.3%, white solid; 1H NMR (300 MHz, CDCl3) δ 8.17 - 8.08 (m, 1H), 8.06 
(d, J = 7.3 Hz, 1H), 7.62 (ddd, J = 8.4, 6.8, 1.4 Hz, 1H), 7.52 (s, 1H), 7.44 - 7.36 (m, 
1H), 7.28 (s, 1H), 7.24 (d, J = 8.4 Hz, 1H), 7.10 (dd, J = 8.5, 1.7 Hz, 1H), 7.02 (d, J = 
3.1 Hz, 1H), 6.44 (d, J = 3.1 Hz, 1H), 5.02 (q, J = 7.1 Hz, 1H), 3.73 (s, 3H), 2.77 (s, 
3H), 1.83 (d, J = 7.1 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 158.23, 151.84, 147.80, 
135.51, 135.06, 128.82, 128.70, 128.24, 128.17, 125.13, 124.94, 123.40, 121.30, 
119.59, 118.82, 108.88, 100.32, 39.68, 32.31, 25.13, 22.01; HR-MS (ESI) m/z: calcd 
for C21H21N2[M+H]+ 301.1699, found 301.1705. 
4.1.8 The general procedures for the preparations of compounds 30a, 30c, 33a and 
33c. 
To solutions of 5-methoylindole or 4-nitro-5-methoylindole (0.68 mmol) in 10 mL 
anhydrous DMF, NaH (60%, 41 mg, 1.02 mmol) was added under N2 atmosphere and 
the mixtures were stirred for 15 min. Then, 4-chloride-2-methylquinoline or newly 
prepared 2-methylquinoline-4-formyl chloride (0.68 mmol) was added and the 
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mixtures were stirred overnight at 50 . Then, the mixtures were diluted with 25 mL 
EtOAc, then washed with water (20 mL × 3 ), saturated brine, dried over anhydrous 
Na2SO4, and concentrated in vacuo, the residues were purified by column 
chromatography with petroleum/ethyl acetate (5:1) to give 30a, 30b, 33a and 33b; 
Then, compounds 30b or 33b (0.24 mmol) was dissolved into 5 mL mixture solvent 
of EtOH and AcOH (1:1), and Fe powder (134 mg, 2.4 mmol) was added in one 
potion. The reactions were stirred for 2 h at 65 , then the solvents were removed in 
vavo and the residues were neutralized by saturated NaHCO3 aqueous. The mixtures 
were filtrated, and the filtrates were extracted with EtOAc (3 × 20 mL). The combined 
organic layers were then washed with saturated brine, dried over anhydrous Na2SO4, 
and concentrated in vacuo to afford the crude products, which were purified by 
column chromatography with petroleum/ethyl acetate (2:1) to give 30c or 33c. 
4.1.8.1 4-(5-methoxy-1H-indol-1-yl)-2-methylquinoline (30a) 
Yield 25.5%, grey solid; 1H NMR (300 MHz, CDCl3) δ 9.87 (s, 1H), 8.20 (d, J = 
3.1 Hz, 1H), 8.17 (d, J = 2.8 Hz, 1H), 8.12 (d, J = 2.3 Hz, 1H), 7.80 (d, J = 7.9 Hz, 
1H), 7.74 (d, J = 8.1 Hz, 1H), 7.55 (t, J = 7.6 Hz, 1H), 7.48 (s, 1H), 7.40 (s, 1H), 7.12 
(dd, J = 8.7, 2.4 Hz, 1H), 3.94 (s, 3H), 2.87 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 
185.53, 158.68, 152.70, 148.30, 135.30, 130.83, 129.63, 127.72, 127.10, 124.13, 
123.49, 122.84, 122.23, 120.29, 119.01, 115.23, 100.63, 55.81, 29.69; HR-MS (ESI) 
m/z: calcd for C19H17N2O[M+H]+ 289.1335, found 289.1342. 
4.1.8.2 5-methoxy-1-(2-methylquinolin-4-yl)-1H-indol-4-amine (30c) 
Yield 20.4% over two steps, yellow oil; 1H NMR (300 MHz, CDCl3) δ 8.08 - 8.02 
(m, 1H), 7.69 - 7.62 (m, 2H), 7.37 - 7.31 (m, 1H), 7.26 (s, 1H), 7.17 (d, J = 3.4 Hz, 
1H), 6.75 (d, J = 8.8 Hz, 1H), 6.60 (d, J = 3.3 Hz, 1H), 6.48 (d, J = 8.8 Hz, 1H), 4.01 
(s, 2H), 3.79 (s, 3H), 2.70 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 159.50, 149.58, 
144.72, 140.32, 133.61, 130.17, 129.06, 128.46, 128.30, 126.22, 123.66, 122.99, 
119.05, 118.89, 110.27, 100.87, 100.39, 57.61, 25.39; HR-MS (ESI) m/z: calcd for 
C19H18N3O[M+H]+ 304.1444, found 304.1448. 
4.1.8.3 (5-methoxy-1H-indol-1-yl)(2-methylquinolin-4-yl)methanone (33a) 
Yield 39.4%, grey solid; 1H NMR (300 MHz, CDCl3) δ 8.48 (s, 1H), 8.16 (d, J = 
8.2 Hz, 1H), 7.83 - 7.73 (m, 2H), 7.55 - 7.50 (m, 1H), 7.46 (s, 1H), 7.13 - 7.04 (m, 
2H), 6.87 (s, 1H), 6.53 (d, J = 3.7 Hz, 1H), 3.92 (s, 3H), 2.85 (s, 3H); 13C NMR (75 
MHz, CDCl3) δ 165.44, 158.07, 156.75, 147.65, 140.24, 131.55, 129.90, 129.72, 
128.76, 126.84, 126.67, 124.12, 122.10, 119.69, 116.96, 113.19, 109.52, 103.60, 
55.21, 24.84; HR-MS (ESI) m/z: calcd for C20H17N2O2[M+H]+ 317.1285, found 
317.1288. 
4.1.8.4 (4-amino-5-methoxy-1H-indol-1-yl)(2-methylquinolin-4-yl)methanone (33c) 
Yield 23.5% over two steps, yellow oil; 1H NMR (300 MHz, CDCl3) δ 8.17 - 8.07 
(m, 1H), 7.94 (s, 1H), 7.76 (d, J = 6.9 Hz, 1H), 7.73 (s, 1H), 7.50 (d, J = 8.2 Hz, 1H), 
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7.44 (d, J = 9.6 Hz, 1H), 6.98 (d, J = 8.8 Hz, 1H), 6.75 (s, 1H), 6.49 (s, 1H), 4.12 (s, 
2H), 3.95 (s, 3H), 2.83 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 166.01, 158.62, 148.15, 
143.52, 140.99, 131.08, 130.37, 129.25, 128.41, 127.12, 125.70, 124.69, 122.59, 
120.14, 119.56, 110.03, 106.57, 106.40, 56.66, 25.42; HR-MS (ESI) m/z: calcd for 
C20H18N3O2[M+H]+ 332.1394, found 332.1393. 
 
4.1.9 The synthesis of 4-(1-(1-(fluoromethyl)-1H-indol-5-yl)vinyl)-2-methylquinoline 
(34a). ClCH2F gas was inlet to a solution of 5 mL DMF in sealed tube under ice-bath 
condition for 5 min, then NaH (60%, 28 mg, 0.70 mmol) and 26d (100 mg, 0.36 
mmol) were added. The mixture was stirred at 80 ℃ for 2 h, which was then diluted 
with 25 mL EtOAc, washed with water (20 mL × 3 ), saturated brine, dried over 
anhydrous Na2SO4, and concentrated in vacuo, and the residue was purified by flash 
column chromatography with petroleum/ethyl acetate (5:1) to give the product 34a as 
white solid, which was unstable in the silicagel column leading to low yield 18.0%; 
1H NMR (300 MHz, CDCl3) δ 8.05 (d, J = 8.4 Hz, 1H), 7.75 (dd, J = 8.4, 1.4 Hz, 1H), 
7.62 (ddd, J = 8.5, 6.9, 1.4 Hz, 1H), 7.45 (d, J = 1.6 Hz, 1H), 7.40 (d, J = 8.6 Hz, 1H), 
7.36 - 7.29 (m, 2H), 7.28 (s, 1H), 7.16 (d, J = 3.4 Hz, 1H), 6.52 - 6.46 (m, 1H), 6.17 (s, 
1H), 5.99 (d, J = 2.6 Hz, 2H), 5.37 (d, J = 1.1 Hz, 1H), 2.78 (s, 3H); 13C NMR (75 
MHz, CDCl3) δ 158.30, 148.67, 147.69, 146.18, 129.10, 128.77, 128.28, 128.20, 
128.15, 125.67, 125.10, 122.08, 121.30, 119.36, 115.30, 108.95, 104.77, 104.74, 
84.66, 82.03, 24.90; HR-MS (ESI) m/z: calcd for C21H18FN2[M+H]+ 317.1449, found 
329.1452. 
 
4.1.10 The synthesis of (5-(1-(2-methylquinolin-4-yl)vinyl)-1H-indol-1-yl)methanol 
(34b). To a solution of 26d (70 mg, 0.25 mmol) in 2 mL EtOH, 1 mL 10% NaOH 
aqueous and 1 mL formaldehyde aqueous were added. The mixture was stirred for 2 h, 
and the precipitates were collected by filtration, washed with water and dried to afford 
34b as pink solid (50 mg, yield 64.9%); 1H NMR (300 MHz, DMSO-d6) δ 7.95 (d, J = 
8.3 Hz, 1H), 7.70 - 7.57 (m, 2H), 7.52 (d, J = 8.4 Hz, 1H), 7.37 (s, 2H), 7.32 (s, 1H), 
7.25 (s, 1H), 6.39 (d, J = 23.4 Hz, 2H), 6.01 (s, 1H), 5.49 (d, J = 6.8 Hz, 2H), 5.31 (s, 
1H), 3.35 (s, 1H), 2.70 (s, 3H); 13C NMR (75 MHz, DMSO-d6) δ 158.66, 148.54, 
147.62, 146.63, 135.22, 131.26, 129.26, 129.07, 128.62, 128.57, 125.71, 125.47, 
124.84, 122.22, 119.77, 118.66, 114.90, 110.57, 101.70, 68.63, 24.79; HR-MS (ESI) 
m/z: calcd for C21H19N2O[M+H]+ 315.1492, found 315.1497. 
4.1.11 The synthesis of 1-(5-(1-(2-methylquinolin-4-yl)vinyl)-1H-indol-1-yl)ethan-1- 
-one (34c). To a solution of 26d (50 mg, 0.18 mmol) in 5 mL DCM, glacial acetic acid 
(22 µL, 0.21 mmol), Et3N (36 µL, 0.54 mmol) and catalytic DMAP were added. The 
mixture was refluxed overnight, which were then diluted with 25 mL EtOAc, washed 
with water (20 mL × 3 ), saturated brine, dried over anhydrous Na2SO4, and 
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concentrated in vacuo. The residue was purified by flash column chromatography 
with petroleum/ethyl acetate (5:1) to give the product 34c as white solid (45 mg, 
78.9%); 1H NMR (300 MHz, CDCl3) δ 8.37 (d, J = 8.7 Hz, 1H), 8.05 (d, J = 8.1 Hz, 
1H), 7.70 (d, J = 8.4 Hz, 1H), 7.62 (ddd, J = 8.4, 6.9, 1.5 Hz, 1H), 7.42 (dd, J = 8.7, 
1.9 Hz, 1H), 7.37 (d, J = 3.7 Hz, 1H), 7.34 (d, J = 1.7 Hz, 1H), 7.30 (d, J = 7.1 Hz, 
1H), 7.28 (s, 1H), 6.51 (d, J = 4.0 Hz, 1H), 6.03 (d, J = 1.1 Hz, 1H), 5.41 (d, J = 1.1 
Hz, 1H), 2.78 (s, 3H), 2.61 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 168.00, 158.30, 
148.30, 147.72, 145.85, 139.98, 135.16, 134.75, 130.11, 128.78, 128.35, 125.56, 
125.37, 125.11, 124.91, 123.17, 122.06, 118.83, 116.08, 108.82, 24.88, 23.39; HR-MS 
(ESI) m/z: calcd for C22H19N2O[M+H]+ 327.1492, found 327.1496. 
 
4.1.12 The synthesis of 4-(1-(1-methyl-1H-indol-5-yl)vinyl)quinoline-2-carbaldehyde 
(35a). To a solution of 27c (100 mg, 0.34 mmol) in 5 mL dioxane, SeO2 (45 mg, 0.4 
mmol) was added. The mixture was refluxed for 2 h, which were then diluted with 25 
mL EtOAc, washed with water (20 mL × 3 ), saturated brine, dried over anhydrous 
Na2SO4, and concentrated in vacuo. Then, the residue was purified by flash column 
chromatography with petroleum/ethyl acetate (20:1) to give the product 35a as white 
solid (40 mg, 38.5%); 1H NMR (300 MHz, CDCl3) δ 10.29 (s, 1H), 8.27 (d, J = 8.2 
Hz, 1H), 8.03 (s, 1H), 7.93 - 7.85 (m, 1H), 7.75 (ddd, J = 8.4, 6.9, 1.4 Hz, 1H), 7.52 - 
7.43 (m, 1H), 7.41 (t, J = 1.2 Hz, 1H), 7.25 (d, J = 5.6 Hz, 1H), 7.23 (d, J = 1.6 Hz, 
1H), 7.03 (d, J = 3.1 Hz, 1H), 6.37 (d, J = 3.1 Hz, 1H), 6.03 (d, J = 1.0 Hz, 1H), 5.37 
(d, J = 1.1 Hz, 1H), 3.78 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 193.51, 151.88, 
150.64, 147.82, 146.23, 136.08, 130.77, 130.08, 129.64, 129.19, 128.78, 128.44, 
127.99, 126.25, 119.89, 119.13, 117.46, 115.35, 108.88, 101.04, 32.43; HR-MS (ESI) 
m/z: calcd for C21H16N2NaO[M+Na]+ 335.1155, found 335.1155. 
 
4.1.13 The synthesis of (4-(1-(1-methyl-1H-indol-5-yl)vinyl)quinolin-2-yl)methanol 
(35b). To a solution of 35a (20 mg, 0.06 mmol) in 10 mL THF, NaBH4 (4.8 mg, 0.12 
mmol) was added. The mixture was stirred for 30 min, which were then quenched 
with NH4Cl aqueous, diluted with 25 mL EtOAc, washed with water (20 mL × 3 ), 
saturated brine, dried over anhydrous Na2SO4, and concentrated in vacuo. The residue 
was purified by flash column chromatography with petroleum/ethyl acetate (2:1) to 
give the product 35b as colorless oil (15 mg, 75%); 1H NMR (300 MHz, CDCl3) δ 
8.10 (d, J = 8.9 Hz, 1H), 7.82 (dd, J = 8.4, 1.4 Hz, 1H), 7.65 (ddd, J = 8.4, 6.9, 1.4 Hz, 
1H), 7.43 (s, 1H), 7.34 (ddd, J = 8.3, 6.9, 1.3 Hz, 1H), 7.27 (s, 1H), 7.26 – 7.23 (m, 
2H), 7.02 (d, J = 3.1 Hz, 1H), 6.38 (d, J = 3.1 Hz, 1H), 5.99 (d, J = 1.2 Hz, 1H), 5.33 
(d, J = 1.2 Hz, 1H), 4.95 (s, 2H), 3.77 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 158.14, 
150.01, 146.62, 145.55, 136.70, 132.66, 129.01, 128.79, 128.30, 126.08, 125.72, 
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125.65, 125.60, 120.96, 119.46, 119.14, 118.17, 108.88, 100.14, 63.62, 32.54; 
HR-MS (ESI) m/z: calcd for C21H19N2O[M+H]+ 315.1492, found 335.1494. 
4.1.14 The general procedures for the preparations of compounds 35c-g and 35i. 
Various C-2 substituted 4-chlorinequinolines were synthesized according to the 
literature report [27]. To the solution of N-tosylhydrazone 37 (150 mg, 0.44 mmol) in 
2 mL dioxane in sealed tube, various 4-chlorinequinolines (0.44 mmol), Xphos (19 
mg, 0.04 mmol), Pd(CH3CN)2Cl2 (6 mg, 0.02 mmol), t-BuOLi (77 mg, 0.97 mmol) 
were added. After stirring for 2 h at 90 ℃, the mixtures were filtered and the filtrates 
were concentrated to afford the crude products, which were purified by column 
chromatography with petroleum/ethyl acetate (5:1) to give compounds 35c-g and 35i 
in good yields. 
4.1.14.1 N, N-dimethyl-4-(1-(1-methyl-1H-indol-5-yl)vinyl)quinolin-2-amine (35c) 
  Yield 80%, yellow solid; 1H NMR (300 MHz, CDCl3) δ 7.72 (d, J = 8.2 Hz, 1H), 
7.54 (dd, J = 8.1, 1.5 Hz, 1H), 7.51 (dd, J = 1.7, 0.7 Hz, 1H), 7.44 (ddd, J = 8.4, 6.9, 
1.5 Hz, 1H), 7.31 (dd, J = 8.7, 1.8 Hz, 1H), 7.21 (s, 1H), 7.01 (d, J = 3.1 Hz, 1H), 
7.00 - 6.93 (m, 1H), 6.90 (s, 1H), 6.37 (dd, J = 3.2, 0.9 Hz, 1H), 5.93 (d, J = 1.4 Hz, 
1H), 5.31 (d, J = 1.4 Hz, 1H), 3.76 (s, 3H), 3.25 (s, 6H); 13C NMR (75 MHz, CDCl3) 
δ 157.10, 149.94, 148.05, 147.49, 136.03, 131.02, 128.99, 128.71, 127.99, 126.01, 
125.79, 121.43, 121.03, 119.91, 119.07, 113.49, 109.07, 108.71, 101.06, 37.63, 32.41; 
HR-MS (ESI) m/z: calcd for C22H22N3[M+H]+ 328.1808, found 328.1814. 
4.1.14.2 2-methoxy-4-(1-(1-methyl-1H-indol-5-yl)vinyl)quinoline (35d)  
  Yield 66.7%, White solid; 1H NMR (300 MHz, CDCl3) δ 7.90 – 7.83 (m, 1H), 7.65 
(dd, J = 8.2, 1.4 Hz, 1H), 7.57 - 7.50 (m, 1H), 7.51 - 7.48 (m, 1H), 7.27 (dd, J = 8.7, 
1.7 Hz, 1H), 7.21 (d, J = 0.9 Hz, 1H), 7.19 - 7.11 (m, 1H), 6.98 (d, J = 3.1 Hz, 1H), 
6.94 (s, 1H), 6.36 (dd, J = 3.1, 0.8 Hz, 1H), 5.93 (d, J = 1.3 Hz, 1H), 5.31 (d, J = 1.3 
Hz, 1H), 4.11 (s, 3H), 3.71 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 161.86, 151.67, 
146.59, 146.48, 136.05, 130.81, 129.03, 128.74, 127.99, 126.91, 126.00, 124.05, 
123.31, 119.90, 119.03, 114.21, 112.78, 108.75, 101.06, 52.89, 32.40; HR-MS (ESI) 
m/z: calcd for C21H19N2O[M+H]+ 315.1492, found315.1493. 
4.1.14.3 N-methyl-4-(1-(1-methyl-1H-indol-5-yl)vinyl)quinolin-2-amine (35e) 
  Yield 45.1%, White solid; 1H NMR (300 MHz, CDCl3) δ 7.72 (dd, J = 8.4, 1.2 Hz, 
1H), 7.56 (dd, J = 8.2, 1.5 Hz, 1H), 7.51 (d, J = 1.7 Hz, 1H), 7.49 - 7.42 (m, 1H), 7.30 
(dd, J = 8.6, 1.7 Hz, 1H), 7.25 (s, 1H), 7.22 (d, J = 8.7 Hz, 1H), 7.06 - 6.94 (m, 2H), 
6.64 (s, 1H), 6.38 (d, J = 3.0 Hz, 1H), 5.92 (d, J = 1.4 Hz, 1H), 5.30 (d, J = 1.3 Hz, 
1H), 3.75 (s, 3H), 3.11 (d, J = 4.9 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 156.96, 
150.09, 147.81, 146.90, 136.01, 130.87, 128.96, 128.79, 127.94, 125.88, 125.66, 
122.31, 121.36, 119.88, 119.01, 113.64, 110.91, 108.66, 101.04, 32.40, 28.26; 
HR-MS (ESI) m/z: calcd for C21H20N3[M+H]+ 314.1652, found 314.1655. 
4.1.14.4 4-(1-(1-methyl-1H-indol-5-yl)vinyl)quinolone (35f) 
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  Yield 64.7%, White solid; 1H NMR (300 MHz, CDCl3) δ 8.85 (d, J = 4.4 Hz, 1H), 
8.05 (dd, J = 8.6, 1.3 Hz, 1H), 7.75 (dd, J = 8.5, 1.4 Hz, 1H), 7.55 (ddd, J = 8.4, 6.8, 
1.5 Hz, 1H), 7.35 (d, J = 1.1 Hz, 1H), 7.29 (d, J = 4.4 Hz, 1H), 7.27 - 7.20 (m, 1H), 
7.17 (d, J = 10.1 Hz, 1H), 7.14 (s, 1H), 6.91 (d, J = 3.1 Hz, 1H), 6.28 (d, J = 3.1 Hz, 
1H), 5.90 (d, J = 1.2 Hz, 1H), 5.24 (d, J = 1.2 Hz, 1H), 3.65 (s, 3H); 13C NMR (75 
MHz, CDCl3) δ 149.70, 149.14, 147.97, 146.52, 136.04, 131.04, 129.12, 129.05, 
128.72, 127.98, 126.91, 126.06, 125.88, 121.27, 119.92, 119.12, 114.61, 108.80, 
101.05, 32.41; HR-MS (ESI) m/z: calcd for C21H17N2[M+H]+ 285.1386, found 
285.1391. 
4.1.14.5 4-(1-(1-methyl-1H-indol-5-yl)vinyl)quinoline-2-carbonitrile (35g) 
Yield 40.7%, White solid; 1H NMR (300 MHz, CDCl3) δ 8.19 (d, J = 8.7 Hz, 1H), 
7.89 (d, J = 7.8 Hz, 1H), 7.79 - 7.73 (m, 1H), 7.69 (s, 1H), 7.52 - 7.45 (m, 1H), 7.39 
(d, J = 1.0 Hz, 1H), 7.26 (s, 1H), 7.20 (dd, J = 8.6, 1.7 Hz, 1H), 7.05 (d, J = 3.1 Hz, 
1H), 6.39 (dd, J = 3.2, 0.9 Hz, 1H), 6.05 (d, J = 0.8 Hz, 1H), 5.36 (d, J = 0.9 Hz, 1H), 
3.79 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 151.04, 148.10, 145.27, 136.15, 133.03, 
130.36, 129.68, 129.40, 128.99, 128.65, 128.02, 127.55, 126.05, 123.33, 119.79, 
119.18, 117.21, 115.88, 109.04, 101.09, 32.47; HR-MS (ESI) m/z: calcd for 
C21H16N3[M+H]+ 310.1339, found 310.1340. 
4.1.14.6 4-(1-(1-methyl-1H-indol-5-yl)vinyl)-2-(trifluoromethyl)quinolone (35i) 
Yield 57.0%, White solid; 1H NMR (300 MHz, CDCl3) δ 8.26 (d, J = 8.5 Hz, 1H), 
7.92 (d, J = 8.5 Hz, 1H), 7.79 - 7.75 (m, 1H), 7.74 (d, J = 4.1 Hz, 1H), 7.47 (ddd, J = 
8.0, 6.6, 1.2 Hz, 1H), 7.44 - 7.40 (m, 1H), 7.25 (d, J = 2.5 Hz, 1H), 7.05 (d, J = 3.1 Hz, 
1H), 6.41 (d, J = 3.1 Hz, 1H), 6.06 (s, 1H), 5.39 (s, 1H), 5.30 (s, 1H), 3.79 (s, 3H); 13C 
NMR (75 MHz, CDCl3) δ 151.58, 147.48, 147.09, 147.02, 145.99, 136.12, 130.58, 
129.95, 129.76, 129.28, 128.01, 127.81, 127.59, 126.01, 125.49, 123.02, 119.84, 
119.16, 116.83, 116.80, 115.50, 108.95, 101.09, 32.43; HR-MS (ESI) m/z: calcd for 
C21H16N3O2[M+H]+ 353.1260, found 353.1266. 
 
4.1.15 The synthesis of 4-(1-(1-methyl-1H-indol-5-yl)vinyl)quinoline-2-carboxamide 
(35h). To a solution of N-tosylhydrazone 37 (118 mg, 0.34 mmol) in 2 mL dioxane in 
sealed tube, 4-chlorine-2-cyanquinoline (80 mg, 0.34 mmol), Xphos (17 mg, 0.03 
mmol), Pd(CH3CN)2Cl2 (9 mg, 0.03 mmol), t-BuOLi (87 mg, 1.09 mmol) were added. 
After stirring for 2 h at 90 ℃, the mixture was filtered and the filtrate was 
concentrated, the residue was purified by column chromatography with 
petroleum/ethyl acetate (5:1) to give 34 mg product 35h as white solid, yield 30.0%; 
1H NMR (300 MHz, CDCl3) δ 8.24 (s, 1H), 8.11 (d, J = 5.0 Hz, 1H), 8.04 (d, J = 8.5 
Hz, 1H), 7.78 (d, J = 9.0 Hz, 1H), 7.64 - 7.57 (m, 1H), 7.34 (t, J = 1.2 Hz, 1H), 7.34 - 
7.27 (m, 1H), 7.16 (d, J = 8.2 Hz, 2H), 6.93 (d, J = 3.1 Hz, 1H), 6.28 (d, J = 3.1 Hz, 
1H), 5.98 (s, 1H), 5.96 - 5.89 (m, 1H), 5.29 (s, 1H), 3.67 (s, 3H); 13C NMR (75 MHz, 
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CDCl3) δ 166.70, 150.70, 148.56, 146.54, 136.04, 130.99, 129.49, 129.27, 129.08, 
128.01, 127.34, 126.10, 119.98, 119.13, 118.93, 115.27, 108.80, 107.66, 101.02, 
98.47, 32.42; HR-MS (ESI) m/z: calcd for C21H17N3NaO[M+Na]+ 350.1264, found 
350.1267. 
 
4.2 Pharmacology 
4.2.1 In vitro antiproliferative assay 
Cells were purchased from Nanjing KeyGen Biotech Co. Ltd. (Nanjing, China). 
The cytotoxicity of the test compounds was determined using the MTT assay. Briefly, 
the cell lines were incubated at 37 °C in a humidified 5% CO2 incubator for 24 h in 
96-microwell plates. After medium removal, 100 mL of culture medium with 0.1% 
DMSO containing the test compounds at different concentrations was added to each 
well and incubated at 37 °C for another 72 h. The MTT (5 mg/mL in PBS) was added 
and incubated for another 4 h, the optical density was detected with a microplate 
reader at 490 nm. The IC50 values were calculated according to the dose-dependent 
curves. All the experiments were repeated in at least three independent experiments.  
 
4.2.2 In vitro tubulin polymerization inhibitory assay 
  An amount of 2 mg/mL tubulin (Cytoskeleton) was resuspended in PEM buffer 
containing 80 mM piperazine-N,N’-bis(2-ethanesulfonic acid) sequisodium salt 
PIPES (pH 6.9), 0.5 mM EGTA, 2 mM MgCl2, and 15% glycerol. Then the mixture 
was preincubated with tested compounds or vehicle DMSO on ice. PEG containing 
GTP was added to the final concentration of 3 mg/mL before detecting the tubulin 
polymerization reaction. After 30 min, the absorbance was detected by a 
spectrophotometer at 340 nm at 37 °C every 2 min for 60 min. The area under the 
curve was used to determine the concentration that inhibited tubulin polymerization 
by 50% (IC50), which was calculated with GraphPad Prism Software version 5.02. 
 
4.2.3 Competitive Inhibition Assays.  
The competitive binding activity of tested compounds was evaluated using a 
radiolabeled [3H] colchicine competition scintillation proximity (SPA) assay. In brief, 
0.08 µM [3H] colchicine was mixed with 27c (1 µM, 5 µM), 34b (1 µM, 5 µM) or 
CA-4 (1 µM, 5 µM) and biotinylated porcine tubulin (0.5 µg) in a buffer of 100 µL 
containing 80 mM PIPES (pH 6.8), 1 mM EGTA, 10% glycerol, 1 mM MgCl2, and 1 
mM GTP for 2 h at 37 °C. Then streptavidin-labeled SPA beads (80 µg) were added 
to each mixture. The radioactive counts were measured directly with a scintillation 
counter. 
 
4.2.4 Immunofluorescence Staining 
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K562 cells were seeded into 6-well plates and then treated with vehicle control 
0.1% DMSO, 34b (1, 2, 4 nM). The cells were fixed with 4% paraformaldehyde and 
then penetrated with PBS for three times. After blocking for 20 min by adding 50-100 
µL goat serum albumin at room temperature, cells were incubated with a monoclonal 
antibody (anti-α-tubulin) at 37 °C for 2 h. Then the cells were washed three times by 
PBS following staining by fluorescence antibody and labeling of nuclei by 
4,6-diamidino-2-phenylindole (DAPI). Cells were finally visualized using an LSM 
570 laser confocal microscope (Carl Zeiss, Germany). 
   
4.2.5 Cell cycle analysis 
K562 cells were seeded into 6-well plates and incubated at 37 °C in a humidified 
5% CO2 incubator for 24 h, and then treated with or without 34b at indicated 
concentrations for another 48 h. The collected cells were fixed by adding 70% ethanol 
at 4 °C for 12 h. Subsequently, the cells were resuspended in PBS containing 100 mL 
RNase A and 400 mL of propidium iodide for 30 min. The DNA content of the cells 
was measured using a FACS Calibur flow cytometer (Bectone Dickinson, San Jose, 
CA, USA). 
 
4.2.6 Cell apoptosis analysis 
After treatment with or without 34b at indicated concentrations for 48 h, the cells 
were washed twice in PBS, centrifuged and resuspended in 500 mL AnnexinV 
binding buffer. The cells were then harvested, washed and stained with 5 mL Annexin 
V-APC and 5 mL 7-AAD in the darkness for 15 min. Apoptosis was analyzed using a 
FACS Calibur flow cytometer (Bectone Dickinson, San Jose, CA, USA). 
 
4.2.7 Wound healing assay 
K562 cells were grown in 6-well plates for 24 h. Scratches were made in 
confluent monolayers using 200 µL pipette tip. Then, wounds were washed twice with 
PBS to remove non-adherent cell debris. The media containing different 
concentrations (1, 2, 4 nM) of the compound 34b were added to the petridishes. Cells 
which migrated across the wound area were photographed using phase contrast 
microscopy at 0 h and 24 h. The migration distance of cells migrated in to the wound 
area was measured manually. 
 
4.2.8 Tube formation assay 
EC Matrigel matrix was thawed at 4 °C overnight, and HUVECs suspended in 
DMEM were seeded in 96-well culture plates at a cell density of 50,000 cells/well 
after polymerization of the Matrigel at 37 °C for 30 min. They were then treated with 
20 µL different concentrations of compound 34b or vehicle for 6 h at 37 °C. Then, the 
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morphological changes of the cells and tubes formed were observed and 
photographed under inverted microscope (OLYMPUS, Japan). 
 
4.2.9 In vivo antitumor evaluation 
Five-week-old male Institute of Cancer Research (ICR) mice were purchased from 
Shanghai SLAC Laboratory Animals Co. Ltd. A total of 1 × 106 H22 cells were 
subcutaneously inoculated into the right flank of ICR mice according to protocols of 
tumor transplant research, to initiate tumor growth. After incubation for one day, mice 
were weighted and at random divided into eight groups of eight animals. The groups 
treated with 27c and 34b were administered 10, 20 mg/kg in a vehicle of 10% 
DMF/2% Tween 80/88% saline, respectively. The positive control group was treated 
with PTX (6 mg/kg) every 2 days by intravenous injection. CA-4 and CA-4P were 
administered 20 mg/kg in a vehicle of 10% DMF/2% Tween 80/88% saline and saline 
solution, respectively. The negative control group received a vehicle of 10% DMF/2% 
Tween 80/88% saline through intravenous injection. Treatments of 27c, 34b, CA-4 
and CA-4P were done at a frequency of intravenous injection one dose per day for a 
total 21 consecutive days while the positive group was treated with PTX one dose per 
two days. The mice were sacrificed after the treatments and the tumors were excised 
and weighed. The inhibition rate was calculated as follows: Tumor inhibitory ratio (%) 
= (1-average tumor weight of treated group/average tumor weight of control group) × 
100%. 
 
4.3 Molecular modeling  
In our study, the X-ray structure of the CA-4-α,β-tubulin complex was 
downloaded from the Protein Data Bank (PDB code 5lyi). The protein was prepared 
by removal of the stathmin-like domain, subunits C and D, water molecules and 
colchicine using Discovery Studio modules. The docking procedure was performed by 
employing DOCK program in Discovery Studio 3.0 software, and the structural image 
was obtained using PyMOL software. 
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Highlights: 
 A series of novel quinoline-indole derivatives have been designed and synthesized.  
 34b showed the most potent in vitro antiproliferative activity. 
 27c and 34b inhibited tubulin polymerization by binding to the colchicine site. 
 34b displayed potent in vitro anti-vascular activity. 
 27c and 34b inhibited tumor growth in H22 liver cancer xenograft mouse model. 
 
